

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

021286/027 633

Application Number

09/844,684

Applicant(s)

Mikayama, et al.

Filing Date

4/27/01

Group Art Unit

1648 1644

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RE 1 P E
JC/83
JUL 20 2001
PATENT & TRADEMARK OFFICE
Stamenkovic, et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas", The EMBO Journal, Vol. 8, no. 5, pp. 1403-1410, 1989.

Clark, et al., "CDw40 and BLCA-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes*", Eur. J. Immunol., 1988, 18: 451-457.

Ledbetter, et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40)", The Journal of Immunology, Vol. 138, pp. 788-794, No. 3, February 1, 1987.

Clark, et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50", Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 4494-4498, June 1986.

PL
Paulie, et al., "A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes", Cancer Immunology Immunother., (1985), 20: 23-28.

EXAMINER

GAMBEL 6/13/03

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (modified)
TO: U.S. Department of Commerce
(PW FORM PAT-1449)

Patent and Trademark Office

DEC 16 2002

Atty.
Dkt. No.

M#

Client Ref.

021286-0276339

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Date: December 9, 2002

Page 1 of 1

Applicant: Mikayama, T., et al.

Appln. No.: 09/844,684

Filing Date: April 27, 2001

Examiner: Philip Gabel Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
M	AR 5,786,456	07/1998	Ledbetter, et al.	530	388.73	09/20/93
	BR 6,004,552	12/1999	de Boer, et al.	424	144.1	06/05/95
	CR 6,051,228	04/2000	Aruffo, et al.	424	144.1	02/19/98
DR						
ER						
FR						
GR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
					Enclosed	No Enclose No
	HR WO 00/75348A1	12/2000	PCT	Siegall, Clay B., et al.	C12N 15/63	
	IR WO 01/83755 A2	11/2001	PCT	Mikayama, T., et al.	C12N 15/13	
	JR WO 01/83755 A3	11/2001	PCT	Mikayama, T., et al.	C12N 15/13	
M	KR WO 02/28904 A2	04/2002	PCT	Chu, K., et al.	C07K 16/28	
LR						
MR						
NR						
OR						
PR						
QR						

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

RR		
SR		
TR		
UR		
VR		
WR		

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

G-1 m/sr 6/13/03



Atty.
Dkt. No.

M#

Client Ref.

021286-0276339

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Date: March 20, 2003

Page 1 of 3

Applicant: Mikayama, T., et al.

Appn. No.: 09/844,684

Filing Date: April 27, 2001

Examiner: Philip Gabel Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available		
						Enclosed	No	Enclose	No
CR	WO 91/09115	06/1991	PCT	Banchereau		Y			
DR	WO 96/33735	10/1996	PCT	Kucherlapati		Y			
ER	WO 96/34096	10/1996	PCT	Kucherlapati		Y			
FR	WO 99/61051	12/1999	PCT	Segal		Y			
GR	WO 00/00156	01/2000	PCT	Wade		Y			
HR	WO 00/75348 A1	12/2000	PCT	Siegall		Y			
IR	WO 01/24823	04/2001	PCT	Keting		Y			
JR	WO 01/56603	08/2001	PCT	Thomas		Y			
KR	WO 02/28904	04/2002	PCT	Chu		Y			
LR	EP 0945 465 A1	09/1999	EP	De Boer		Y			
MR	EP 0972 445 A1	01/2000	EP	Tomizuka		Y			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

NR	Kwekkeboom, et al., "Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction," <i>Eur. J. Immunol.</i> (1994), Vol. 24, pp. 508-517.	Y	
OR	Hasbold, et al., "Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4," <i>Eur. J. Immunol.</i> (1998), Vol. 28, pp. 1040-1051.	Y	
PR	Pound, et al., "Minimal cross-linking and epitope requirements for D40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells," <i>Int'l Immunol.</i> (1999), Vol. 11, No. 1, pp. 11-20.	Y	
QR	Francisco, et al., "Agonistic Properties and <i>In Vivo</i> Antitumor of the Anti-CD40 Antibody SGN-14," <i>Cancer Research</i> , (June 15, 2000), Vol. 60, pp. 3225-3231.	Y	
RR	Romano, et al., "Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells," <i>Blood</i> , (August 1, 1998) Vol. 98, No. 3, pp. 990-995.	Y	
SR	Hirano, et al., "Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand," <i>Blood</i> , (May 1, 1999), Vol. 93, No. 9, pp. 2999-3007.	Y	

Gambel 6/13/02

PL	TR	Francisco, et al., "Construction, Expression, and Characterization of G1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1," <i>Journal of Biological Chemistry</i> , (Sept. 26, 1997), Vol. 272, No. 39, pp. 24165-24169.	Y	inactivating
104 MAR 14 2003 PATIENT & T. ADAMANTES	UPC	Maxwell, et al., "Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity," <i>J. Immunol.</i> , (May 1, 2002), Vol. 168, No. 9, pp. 4372-4381.	Y	
	VR	Simonsson, et al., "Single, Antigen-Specific B Cells Used to Generate Fab Fragments Using CD40-Mediated Amplification or Direct PCR Cloning," <i>BioTechniques</i> , (1995), Vol. 18, No. 5, pp. 862-869.	Y	
	WR	Dullforce, et al., "Enhancement of T cell-independent immune responses <i>in vivo</i> by CD 40 antibodies," <i>Nature Medicine</i> , (Jan. 1998), Vol. 4, No. 1, pp. 88 - 91.	Y	
	XR	Erickson, et al., "Short-circuiting long-lived humoral immunity by the heightened engagement of CD40," <i>The J. of Clinical Investigation</i> , (March, 2002), Vol. 109, No. 5, pp. 613-620.	Y	
	YR	Murphy, et al., "Antibodies to CD40 Prevent Epstein-Barr Virus- Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes," <i>Blood</i> , (September 1, 1995), Vol. 86, No. 5, pp. 1946-1953.	Y	RECEIVED MAR 15 2003 BDS CENTER 1800/2900
	ZR	Funakoshi, et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," <i>J. of Immunology</i> , (1996) Vol. 19, No. 2, pp. 93-101.	Y	
	AAR	Schwabe, et al., "Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 Antibodies," <i>Hybridoma</i> , (1997), Vol. 16, No. 13, pp. 217-226.	Y	
	BBR	Funakoshi, et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," <i>Blood</i> , (May 15, 1994), Vol. 83, No. 10, pp. 2787-2794.	Y	
	CCR	Rolink, et al., "The SCID but Not the RAG-2 Gene Product Is Required for S μ -S ϵ Heavy Chain Class Switching," <i>Immunity</i> , (October, 1996) Vol. 5, pp. 319-330.	Y	
	DDR	Kwekkeboom, et al., "CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells," <i>Immunology</i> , (1993), Vol. 79, pp. 439-444.	Y	
	EER	Zhou, et al., "An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line," <i>Hybridoma</i> , Vol. 18, No. 6, 1999, pp. 471-478.	Y	
	FFR	Heath, et al., "Monoclonal antibodies to murine CD40 define two distinct functional epitopes," <i>Eur. J. Immunology</i> , (1994) Vol. 24, pp. 1828-1834.	Y	
	GGR	Mazzei, et al., "Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active," <i>Journal of Biological Chemistry</i> , (March 31, 1995), Vol. 270, No. 13, pp. 7025-7028.	Y	
	HHR	Hasbold, et al., "Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies," <i>Eur. J. Immunology</i> , (1994) Vol. 24, pp. 1835-1842.	Y	
	IIR	Weng, et al., "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," Program of the 43 rd Annual Meeting of The American Society of Hematology, (December 7-11, 2001), Abstract No. 1947, page 466a.	Y	
	JJR	Ledbetter, et al., "Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5," <i>Critical Reviews in Immunology</i> , (1997), Vol. 17, pp. 427-435.	Y	
	KKR	de Boer, et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," <i>Journal of Immunological Methods</i> , (1992) Vol. 152, pp. 15-23.	Y	
	LLR	Karlsson, et al., "Selection of human single chain antibodies against CD-40," <i>Immunology Letters</i> , Vol. 73, Nos. 2,3, Abstract No. 358.	Y	
PL	MMR	Sotomayor, et al., "Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through <i>in vivo</i> ligation of CD40," <i>Nature</i> , (July, 1999), Vol. 399, No. 7, pp. 780-787.	Y	

Gmuzer 6/13/03

ACTIVATION

PERIPHERAL

PC	NNR	Diehl, et al., "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy," <u>Nature Medicine</u> , (July 1999) Vol. 5, No. 7, pp. 774-779. tolerance and	Y		
1 P E MAR 24 2003 P.M. & T. D.F.M.H.	OOR	Schoenberger, et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," <u>Nature</u> , (June 4, 1998), Vol. 393, pp.480-483.	Y		
	PPR	van Mierlo, et al. "CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity," <u>PNAS</u> , (April 16, 2002) Vol. 99, No. 8, pp. 5561-5566.	Y		
	OOR	An, et al., "Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos - Burkitt Lymphoma B Cells," <u>Cellular Immunology</u> , (1997) Vol. 181, pp. 139-152.	Y		
	RRR	Barr, et al., "Functional activity of CD40 antibodies correlates to the position of binding relative to CD154," <u>Immunology</u> , (2001) Vol. 102, pp. 39-43.	Y		
	SSR	Baccam, et al., "Membrane-bound CD154, but not CD40-specific antibody, mediates NF- κ B-independent IL-6 production in B cells," <u>Er. J. Immunol.</u> , (1999), Vol. 29, pp. 3855-3866.	Y		
	TTR	Kedl, et al., "CD40 stimulation accelerates deletion of tumor specific CD8+ T cells in the absence of tumor-antigen vaccination," <u>PNAS</u> , (September 11, 2001) Vol. 98, No. 19, pp. 10811-10816.	Y		
	UUR	Tomizuka, et al., "Double trans-chromosomal mice: Maintenance of two individual human chromosome fragments containing Ig-heavy and κ loci and expression of fully human antibodies," <u>PNAS</u> , (January 18, 2000) Vol. 97, No. 2, pp. 722-727.	Y		
M	VVR	Boon, et al., "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys," <u>Toxicology</u> , (2002), Vol. 174, pp. 53-65.	Y		
	WWR				
	XXR				
	YYR				
	ZZR				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

GMBCL 6/12/03

RECEIVED
MAR 25 2003
TECH CENTER 1600/2000